BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 25679996)

  • 1. Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature.
    Lamartina L; Durante C; Filetti S; Cooper DS
    J Clin Endocrinol Metab; 2015 May; 100(5):1748-61. PubMed ID: 25679996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioiodine remnant ablation in low-risk differentiated thyroid cancer: the "con" point of view.
    Lamartina L; Cooper DS
    Endocrine; 2015 Sep; 50(1):67-71. PubMed ID: 25576046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postoperative Thyroglobulin and Neck Ultrasound in the Risk Restratification and Decision to Perform 131I Ablation.
    Matrone A; Gambale C; Piaggi P; Viola D; Giani C; Agate L; Bottici V; Bianchi F; Materazzi G; Vitti P; Molinaro E; Elisei R
    J Clin Endocrinol Metab; 2017 Mar; 102(3):893-902. PubMed ID: 27929713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low but measurable stimulated serum thyroglobulin levels <2 µg/L frequently predict incomplete response in differentiated thyroid cancer patients.
    Aldawish M; Jha N; McEwan AJ; Severin D; Ghosh S; Morrish DW
    Endocr Res; 2014; 39(4):157-63. PubMed ID: 24460082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement?
    Durante C; Montesano T; Attard M; Torlontano M; Monzani F; Costante G; Meringolo D; Ferdeghini M; Tumino S; Lamartina L; Paciaroni A; Massa M; Giacomelli L; Ronga G; Filetti S;
    J Clin Endocrinol Metab; 2012 Aug; 97(8):2748-53. PubMed ID: 22679061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioiodine remnant ablation in low-risk differentiated thyroid cancer patients who had R0 dissection is an over treatment.
    Bal C; Ballal S; Soundararajan R; Chopra S; Garg A
    Cancer Med; 2015 Jul; 4(7):1031-8. PubMed ID: 25755077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence.
    Hugo J; Robenshtok E; Grewal R; Larson S; Tuttle RM
    Thyroid; 2012 Oct; 22(10):1007-15. PubMed ID: 22873801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioiodine remnant ablation in low-risk differentiated thyroid cancer.
    Saengsuda Y
    J Med Assoc Thai; 2013 May; 96(5):614-24. PubMed ID: 23745318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of early vs late postoperative radioiodine remnant ablation on final outcome in patients with low-risk well-differentiated thyroid cancer.
    Tsirona S; Vlassopoulou V; Tzanela M; Rondogianni P; Ioannidis G; Vassilopoulos C; Botoula E; Trivizas P; Datseris I; Tsagarakis S
    Clin Endocrinol (Oxf); 2014 Mar; 80(3):459-63. PubMed ID: 23895145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Postoperative radioiodine ablation in patients with low risk differentiated thyroid carcinoma].
    Díez JJ; Grande E; Iglesias P
    Med Clin (Barc); 2015 Jan; 144(1):35-41. PubMed ID: 24613061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DELAYED 131-I FIRST TREATMENT AFTER SURGERY HAS NO IMPACT ON THE MEDIAN TERM OUTCOME OF PATIENTS WITH INTERMEDIATE RISK DIFFERENTIATED THYROID CANCER.
    Matrone A; Gambale C; Torregrossa L; Piaggi P; Bianchi F; Valerio L; Viola D; Agate L; Molinaro E; Materazzi G; Basolo F; Vitti P; Elisei R
    Endocr Pract; 2020 Jan; 26(1):58-71. PubMed ID: 31557080
    [No Abstract]   [Full Text] [Related]  

  • 12. Radioiodine post-surgical remnant ablation in patients with differentiated thyroid cancer: news from the last 10 years.
    Molinaro E; Pieruzzi L; Viola D
    J Endocrinol Invest; 2012; 35(6 Suppl):16-20. PubMed ID: 23014069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioiodine Uptake and Thyroglobulin-Guided Radioiodine Remnant Ablation in Patients with Differentiated Thyroid Cancer: A Prospective, Randomized, Open-Label, Controlled Trial.
    Jin Y; Ruan M; Cheng L; Fu H; Liu M; Sheng S; Chen L
    Thyroid; 2019 Jan; 29(1):101-110. PubMed ID: 30560716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma.
    Vaisman A; Orlov S; Yip J; Hu C; Lim T; Dowar M; Freeman JL; Walfish PG
    Head Neck; 2010 Jun; 32(6):689-98. PubMed ID: 20187016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of [(18)F]-fluorodeoxy-D-glucose positron emission tomography and computed tomography in the early detection of persistent/recurrent thyroid carcinoma in intermediate-to-high risk patients following initial radioactive iodine ablation therapy.
    Kim MH; O JH; Ko SH; Bae JS; Lim DJ; Kim SH; Baek KH; Lee JM; Kang MI; Cha BY; Lee KW
    Thyroid; 2012 Feb; 22(2):157-64. PubMed ID: 22224820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioiodine remnant ablation: current indications and dosing regimens.
    Haugen BR
    Endocr Pract; 2012; 18(4):604-10. PubMed ID: 22849876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation.
    Vrachimis A; Schober O; Riemann B
    Nuklearmedizin; 2012; 51(3):67-72. PubMed ID: 22294096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan.
    Chao M
    Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):438-47. PubMed ID: 20561773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
    Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer.
    Sawka AM; Brierley JD; Tsang RW; Thabane L; Rotstein L; Gafni A; Straus S; Goldstein DP
    Endocrinol Metab Clin North Am; 2008 Jun; 37(2):457-80, x. PubMed ID: 18502337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.